AlloVir (formerly ViraCyte) is a company that develops and delivers transformative cell therapies for patients suffering from life-threatening virus-associated diseases. It focuses on the clinical development of novel cell therapies designed to restore natural T-cell immunity against devastating virus-associated diseases in immunocompromised patients, including stem cell and organ transplant recipients.
|Employees (est.) (Apr 2020)||22|
AlloVir total Funding
AlloVir latest funding size
Time since last funding
|a year ago|
|Redmile Group, Invus, F2 Ventures, EcoR1 Capital, Cancer Prevention and Research Institute of Texas, Fidelity Management and Research Company, Leerink Partners, Gilead Sciences, Samsara BioCapital|
AlloVir has 76 Twitter Followers. The number of followers has increased 83.1% month over month and increased 303% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was AlloVir founded?
AlloVir was founded in 2013.
Who are AlloVir key executives?
AlloVir's key executives are David Hallal, Ann Leen and Vikas Sinha.
How many employees does AlloVir have?
AlloVir has 22 employees.
Who are AlloVir competitors?
Competitors of AlloVir include NorInvent, Glycostem and Elpiscience Biopharmaceuticals.
Where is AlloVir headquarters?
AlloVir headquarters is located at 2925 Richmond Ave, Houston.
Where are AlloVir offices?
AlloVir has an office in Houston.
How many offices does AlloVir have?
AlloVir has 1 office.
Receive alerts for 300+ data fields across thousands of companies